Abstract:
CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have structure (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein n , m , A, B, C, R, R1, R2 and Ar are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
Abstract:
The invention relates to core-extended perylene bisimides of formula (I) and (II), wherein R and R independently represent unsubstituted or substituted C1-C24alkyl, C1-C24cycloalkyl or C6-C10aryl and A and A independently represent -S-, -S-S-, -CH=CH-, R OOC-C(-)=C(-)-COOR , -N=N- or -N(R )- or a compound selected from the group consisting of organic radicals of formulae (III), (IV), (V), (VI) and (VII), wherein R represents hydrogen, C1-C24alkyl or C1-C24cycloalkyl, and R represents unsubstituted or substituted C1-C24alkyl, C1-C24cycloalkyl, phenyl, benzyl, -CO-C1-C4alkyl, -CO-C6H5 or C1-C4alkyl carboxylic acid-(C1-C4alkyl)-ester and A represents a compound having formulae (III), (IV) or (V), in addition to intermediate products for the production of the compounds. The invention also relates to a method for producing said intermediate products and to a method for the production of compounds (I) and (II) as well as to their uses as colorants.
Abstract:
Asmarine A and B, novel cytotoxic diterpene-alkaloids, have been isolated from the sponge Raspailia sp. The structure of these compounds have been established on the basis of NMR data and confirmed by X-ray analysis. Also claimed are compounds (I) or (II), wherein R represents hydrogen or lower alkyl or lower alkanoyl; R represents hydrogen or lower alkyl; R is either an alkyl or a cycloalkyl group containing one or more isopreneunits, or a monoterpene or a sesquiterpene or a sesquiterpene or a diterpene group; R or R represent hydrogen or lower alkyl; R represents lower alkyl; X represents F or Cl or Br or (I).
Abstract translation:Asmarine A和B,新型细胞毒二萜生物碱已从海绵Raspailia sp。 这些化合物的结构已经建立在NMR数据的基础上,并通过X射线分析证实。 还要求的是化合物(I)或(II),其中R 1表示氢或低级烷基或低级烷酰基; R 2表示氢或低级烷基; R 3是含有一个或多个异戊二烯单元或单萜或倍半萜烯或倍半萜烯或二萜烯基团的烷基或环烷基; R 4或R 5表示氢或低级烷基; R 6表示低级烷基; X表示F或Cl或Br或(I)。
Abstract:
Disclosed is a method for preventing and/or treating a disease or disorder associated with a defect in hemoglobin protein activity or expression or innate immune response, type 1 or type 3 immunity related immune disorder, which comprises administering to a subject in need thereof a therapeutically effective amount of a substance X or a pharmaceutical composition comprising the substance X; the substance X is a compound of Formula I, a pharmaceutically acceptable salt or solvate thereof.
Abstract:
The present application relates to compounds of Formula I having a negative singlet-triplet gap and a positive oscillator strength. The present application also relates to use of the compounds of Formula (I) in photocatalysis and in OLEDs as emitters and/or dopants.
Abstract:
Die Erfindung betrifft schwefelreiche Polymere aus mit Schwefel vernetzten Linkermolekülen der Formel (I) (Hexaallylmelem) und/oder (II) (Hexaallylmelamin) sowie Polymergemische und Komposite damit, sowie ein Verfahren zu deren Herstellung und deren Verwendung. Die Verwendung der Linkermoleküle der Formel (I) und/oder (II) zur Herstellung der schwefelreichen Polymere wird offenbart. Gegenstand der Erfindung ist auch ein Polymerlinker der Formel (I).